Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 5, 2003, Pages 727-729

  Sundberg, Åsa Liljegren ^a   Almqvist, Ylva ^a   Tolmachev, Vladimir ^a   Carlsson, Jörgen ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

EGFR; Gefitinib; Glioma

Indexed keywords

ASTATINE 211; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL CULTURE; CELL GROWTH; CELL LINE; GLIOMA CELL; HUMAN; HUMAN CELL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TRANSPORT; TUMOR GROWTH;

EID: 0037569521     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1129-x     Document Type: Article

References (12)

1. Boiardi A, Silvani A, Pozzi A, Fariselli L, Broggi G, Salmaggi A. Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies. J Neurooncol 1999; 41:151-157.
2. Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, GarciaTurner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE 2nd, Provenzale JM, Zalutsky MR, Bigner DD. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 2000; 18:3862-3872.
3. 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 2001; 16:227-235.
4. 90Y: a phase I study. Clin Cancer Res 1999; 5(10 Suppl):3275s-3280s.
5. 90Y]DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC). Swiss Med Wkly 2001; 131:640-644.
6. Barker FG 2nd, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, Wara WM, Berger MS, Chen P, Israel MA, Aldape KD. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001; 51:410-418.
7. Huncharek M, Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res 2000; 12:107-112.
8. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol 1999; 1:44-51.
9. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6:217-223; discussion 223-224.
10. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D, Pepe S, Bianco AR, Ciardiello F. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8:3250-3258.
11. Lichtner RB, Menrad A, Sommer A, Klar U, Schneider MR. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 2001; 61:5790-5795.
12. 125I]iodobenzoyl labeled A6H F(ab')2. Nucl Med Biol 1993; 20: 917-927.